

Kielpin, 11.10.2017

*Purchaser:*

**Celon Pharma S.A.**

Mokra 41A

05-092 Łomianki / Kielpin

tel.: +48 22 751 74 78

fax: +48 22 751 74 77

e-mail:  [paulina.gruszka@celonpharma.com](mailto:paulina.gruszka@celonpharma.com)

National Court Register number (KRS): 0000437778

Tax ID number (NIP): 118 - 16 - 42 - 061

### **REQUEST FOR QUOTATION (RfQ) no. 52/2017/M/CELONKO**

In relation to the planned implementation of the project Development of novel biomarkers and innovative FGFR kinases inhibitor as an anti-cancer therapy by Celon Pharma S.A. as part of the 2nd edition of the contest in the research and development program Prevention and treatment of civilization diseases - STRATEGMED (hereinafter "the Project"), we hereby request your quotation for:

#### **Kinome Selectivity Screening study**

##### **Obligatory parameter:**

- a. Number of kinases in the panel should cover at least 75% of known human kinome, excluding mutant versions of known kinases,
- b. The assay should be ATP-independent.

##### **Additional parameters:**

- c. Inhibition of a kinase by the compound should be measured as a percent of a proper control.
- d. Study mode should allow for discrimination between different binding modes of tested compound.
- e. A particular assay within the study should be marked with significant signal-to-noise ratio, e.g. described by a Z' factor of at least 0,7.
- f. The method used for dissociation constant determination should have a broad dynamic range of quantitatively measured interaction affinities (at least 4 logs).

A detailed protocol of the study will be agreed with the successful bidder on signature of the contract.

**Requirements to be met by bidders:**

1. The Bidder should have the necessary experience to deliver the subject of the order.
2. The Bidder should hold all licences required by law to deliver the subject of the order.
3. The Bidder's financial and economic position should ensure successful implementation of the order.

**Address and date for submitting the bids:**

1. Bids must be submitted by electronic mail to [paulina.gruszka@celonpharma.com](mailto:paulina.gruszka@celonpharma.com)
2. Bid must be submitted by the **18 October 2017** at the latest.
3. Bids submitted after the aforementioned date will not be considered.
4. Bids will be evaluated at the Purchaser's office within 7 days from submission deadline.
5. The final decision will be communicated to all Bidders by electronic mail within 7 days from submission deadline.
6. For further information on the Project, please contact dr. Aleksandra Stańczak [aleksandra.stanczak@celonpharma.com](mailto:aleksandra.stanczak@celonpharma.com)

**Presentation of the bids:**

1. Each Bidder may submit only one bid.
2. The bid must contain the date of preparation, the Bidder's address, telephone number, email address, tax ID number.
3. The bid must be valid until the end of the year 2017.
4. The bid must contain:
  - if submitted by a Bidder operating in Poland, the gross and net bid price and due VAT offered for delivery of the subject of the order on accordance with the requirements set forth herein,
  - if submitted by a Bidder operating outside Poland, the net bid price and information that not VAT or other taxes have been included in the price quotation.
5. The bid should contain the RfQ no. in the title. The RfQ no. must also appear in the titles of invoices.
6. "The Statement on absence of personal or capital ties with the Purchaser" should be submitted along with the bid.

**Note:**

1. The Purchaser will place the order with the bidder whose bid meets all the requirements set forth in this RfQ and is deemed the best relative to the selection criteria set forth herein.
2. The Purchaser reserves the right to close the bidding process without selecting the successful Bidder. In such case the purchaser doesn't need to specify its reasons for doing so.
3. In the course of evaluation and assessment of the bids, the Purchaser may request that the bidders provide clarifications regarding their bids.
4. The bidder may alter or withdraw its offer before the submission deadline.
5. Bids submitted past the submission deadline will not be considered.
6. Bids that do not meet the formal requirements set forth herein will not be considered.
7. The Purchaser does not accept variant bids.
8. The Purchaser does not accept partial bids.

9. The Purchaser permits rejecting bids whose essential content clearly raises reasonable doubts.

The quote will be selected based on the following criteria:

Nr	KRYTERIUM	System przyznawania punktów
1.	Price	<p>Price „P” - max. 5 points – this is 50% of the maximum number of points to gain</p> <p>Scoring in the price criterion will be as follows: the lowest price for conducting the study proposed by the tenderer will be considered 100%, and the maximum number of points. Other proposals will be assessed based on the formula:</p> $P = 5 - \left( \frac{\text{price}_{\text{service}} - \text{price}_{\text{lowest}}}{\text{price}_{\text{lowest}}} * 5 \right)$ <p>Where:</p> <p>Price<sub>lowest</sub> – the lowest price among given quotes.</p> <p>Price<sub>service</sub> – price for the given tenderer.</p> <p>Quotes with negative score given based on the formula above will be scored zero points in price criterion.</p>
2.	Quality	<p>Quality „Q” – max. a total of 5 points – this is 50% of the maximum number of points to gain</p> <p>Scoring in the quality criterion will be given for a concordance with the points detailing the study:</p> <p>a) The proposals will be put in decreasing order starting from panel with the highest number of kinases. The proposal with highest number of kinases in the panel will be given 1 points, the second proposal will be given 0,9 points, the third 0,8 points etc.).</p> <p>b) +1 point for parameters described in c-f.</p>

The final score will be calculated by substituting the data obtained above to the following formula:

Total points = Criterion “P” + Criterion “Q”